US Patent

US11504365 — Use of tivozanib to treat subjects with refractory cancer

Method of Use · Assigned to Aveo Pharmaceuticals Inc · Expires 2039-11-05 · 13y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using tivozanib to treat subjects with refractory advanced renal cell carcinoma.

USPTO Abstract

Disclosed is a method of treating cancer, e.g., refractory cancer, with tivozanib. The methods disclosed include, for example, administering tivozanib as a second or third-line therapy to subjects suffering from refractory advanced renal cell carcinoma where traditional therapies as well as more recent targeted and immune-oncology therapies have not adequately treated the subject.

Drugs covered by this patent

tivozanib-hydrochloride (TIVOZANIB HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3476`	—	tivozanib-hydrochloride
`U-3476`	—	tivozanib-hydrochloride

Patent Metadata

Patent number: US11504365
Jurisdiction: US
Classification: Method of Use
Expires: 2039-11-05
Drug substance claim: No
Drug product claim: No
Assignee: Aveo Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.